A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Last updated:
2026-08-15
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A MASTER PROTOCOL FOR PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE WEEKLY ELORALINTIDE IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE OBSTRUCTIVE SLEEP APNEA, AND OBESITY OR OVERWEIGHT (ENLIGHTEN-3)

Intervention/treatment:
ELORALINTIDE (LY3841136)
Medical condition:
SLEEP APNEA
Protocol code:
J3R-MC-YDAO
Control number:
306473
Status:
Recruiting
Approved:
March 06, 2026
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT07369011
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Role
CONTACT
Phone:
1-317-615-4559
Name
Physicians interested in becoming principal investigators please contact
Role
CONTACT
Sponsor
ELI LILLY CANADA INC

Locations

Alpha Recherche Clinique
Québec, G2J 0C4
Recruiting
Name
Nancy Labrecque
Role
PRINCIPAL_INVESTIGATOR
Alpha Recherche Clinique - Lévis
Lévis, G6V 0C9
Recruiting
Role
CONTACT
Phone:
418-380-1112
Name
Dominique Deschênes
Role
PRINCIPAL_INVESTIGATOR
C.I.C. Mauricie inc.
Trois-Rivières, G8T 7A1
Recruiting
Name
Pierre-Alexandre Menard
Role
PRINCIPAL_INVESTIGATOR
Phone:
4164657936
C.I.C. Saint-Laurent
Saint-Laurent, H4R 3C8
Recruiting
Name
Eve Melancon
Role
CONTACT
Phone:
8193731128
Name
Emilie Millaire
Role
PRINCIPAL_INVESTIGATOR
Maple Leaf Research
Toronto, M5G 1K2
Recruiting
Role
CONTACT
Phone:
4164657936
Name
Graham Smith
Role
PRINCIPAL_INVESTIGATOR
MyCliniResearch, Inc.
Calgary, T2Z 3R6
Recruiting
Role
CONTACT
Phone:
5873320600
Name
Wilfred Alonso
Role
PRINCIPAL_INVESTIGATOR
Did you find what you were looking for?

Contacts and resources